Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tam

Showing results (851-860 of 922) with videos related to

Pageof 93
Sort By:
European Journal of Human Genetics : EJHG|June 10, 2011
A dominant mutation in RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with choroidal involvementSara J Bowne, Marian M Humphries, Lori S Sullivan, et al.
Nature Communications|March 18, 2017
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemiaPaul Yeh, Tane Hunter, Devbarna Sinha, et al.
Internal Medicine Journal|December 26, 2023
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignanciesAshlea Campbell, Benjamin Teh, Stephen Mulligan, et al.
The Journal of Allergy and Clinical Immunology. Global|April 23, 2026
Four doses of coronavirus disease 2019 vaccination for patients with inborn errors of immunity compared to 3 doses for healthy individualsJeffery C H Chan, Samuel M S Cheng, Daniel Leung, et al.
The Lancet. Oncology|January 17, 2017
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F Seymour, Shuo Ma, Danielle M Brander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Barbara Eichhorst, Jennifer R Brown, et al.
Lancet (London, England)|December 5, 2003
Genomic characterisation of the severe acute respiratory syndrome coronavirus of Amoy Gardens outbreak in Hong KongS S C Chim, S K W Tsui, K C A Chan, et al.
Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.
Seminars in Hematology|May 5, 2023
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patientsS D'Sa, J V Matous, R Advani, et al.
Transplantation and Cellular Therapy|November 28, 2025
Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell TherapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
Pageof 93

Showing results (851-860 of 922) with videos related to

Sort By:
Pageof 93
European Journal of Human Genetics : EJHG|June 10, 2011
A dominant mutation in RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with choroidal involvementSara J Bowne, Marian M Humphries, Lori S Sullivan, et al.
Nature Communications|March 18, 2017
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemiaPaul Yeh, Tane Hunter, Devbarna Sinha, et al.
Internal Medicine Journal|December 26, 2023
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignanciesAshlea Campbell, Benjamin Teh, Stephen Mulligan, et al.
The Journal of Allergy and Clinical Immunology. Global|April 23, 2026
Four doses of coronavirus disease 2019 vaccination for patients with inborn errors of immunity compared to 3 doses for healthy individualsJeffery C H Chan, Samuel M S Cheng, Daniel Leung, et al.
The Lancet. Oncology|January 17, 2017
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F Seymour, Shuo Ma, Danielle M Brander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Barbara Eichhorst, Jennifer R Brown, et al.
Lancet (London, England)|December 5, 2003
Genomic characterisation of the severe acute respiratory syndrome coronavirus of Amoy Gardens outbreak in Hong KongS S C Chim, S K W Tsui, K C A Chan, et al.
Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.
Seminars in Hematology|May 5, 2023
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patientsS D'Sa, J V Matous, R Advani, et al.
Transplantation and Cellular Therapy|November 28, 2025
Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell TherapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
Pageof 93